Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
gptkb:U._S._government
|
| gptkbp:age |
12 years and older
|
| gptkbp:approves |
gptkb:FDA
December 2020 |
| gptkbp:average_temperature |
-70 degrees Celsius
|
| gptkbp:brand |
gptkb:Comirnaty
|
| gptkbp:clinical_trial |
multiple countries
Phase 3 44,000 published in medical journals |
| gptkbp:committee |
ACIP recommendations
|
| gptkbp:communication |
public information campaigns
|
| gptkbp:controversy |
some public skepticism
|
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:distribution |
distributed through COVAX
|
| gptkbp:dosage_form |
gptkb:battle
2 |
| gptkbp:duration |
6 months
|
| gptkbp:effective_date |
August 2021
|
| gptkbp:emergency_services |
gptkb:battle
|
| gptkbp:has_variants |
decreased efficacy against some variants
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pfizer's COVID-19 vaccine
|
| gptkbp:incubation_period |
3 weeks apart
|
| gptkbp:is_effective_against |
95% in preventing COVID-19
|
| gptkbp:is_vulnerable_to |
global
community outreach programs international regulatory bodies global health organizations messenger RNA widely accepted preventive vaccine significant impact on public health collaboration with governments reduced hospitalization rates contributed to herd immunity ongoing safety assessments reduced severe disease cases U. S. government funding complex logistics CDC monitoring effective against severe illness long-term studies ongoing. |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
over 100 countries
|
| gptkbp:moral |
equitable distribution issues
|
| gptkbp:partnership |
Bio N Tech
|
| gptkbp:published_by |
peer-reviewed studies
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever joint pain chills injection site pain |
| gptkbp:storage |
requires ultra-cold storage
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:technology |
lipid nanoparticle delivery system
|
| gptkbp:type |
gptkb:vaccine
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
5
|